MUC1-C oncoprotein as a target in breast cancer: Activation of signaling pathways and therapeutic approaches

Oncogene

Volumn 32, Issue 9, 2013, Pages 1073-1081

  Kufe, D W ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

breast cancer; MUC1; oncoprotein; signaling pathways; targeted agents

Indexed keywords

BETA CATENIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUC1 C PROTEIN; MUCIN 1; ONCOPROTEIN; STAT PROTEIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

BREAST CANCER; CELL MEMBRANE; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; MUCIN-1; ONCOGENE PROTEINS; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION;

EID: 84874743726     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.158     Document Type: Review

References (72)

1. Kufe D. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874-885.
2. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3: 223-232.
3. Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J. Cellassociated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 1992; 267: 6171-6177.
4. Levitin F, Stern O, Weiss M, Gil-Henn C, Ziv R, Prokocimer Z et al. The MUC1 SEA module is a self-cleaving domain. J Biol Chem 2005; 280: 33374-33386.
5. Macao B, Johansson DG, Hansson GC, Hard T. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol 2006; 13: 71-76.
6. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci USA 1988; 85: 2320-2323.
7. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell JA. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988; 263: 12820-12823.
8. Abe M, Kufe D. Structural analysis of the DF3 human breast carcinoma associated protein. Cancer Res 1989; 49: 2834-2839.
9. Hayes DF, Sekine H, Ohno T, Abe M, Keefe K, Kufe DW. Use of a murine monoclonal antibody for detection of circulating DF3 antigen levels in breast cancer patients. J Clin Invest 1985; 75: 1671-1678.
10. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005; 18: 1295-1304.
11. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001; 91: 1973-1982.
12. McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 1995; 26: 432-439.
13. Merlo G, Siddiqui J, Cropp C, Liscia DS, Lidereau R, Callahan R et al. DF3 tumorassociated antigen gene is located in a region on chromosome 1q frequently altered in primary human breast cancer. Cancer Res 1989; 49: 6966-6971.
14. Bieche I, Lidereau R. A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors. Cancer Genet Cytogenet 1997; 98: 75-80.
15. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 2010; 201: 102-110.
16. Abe M, Kufe D. Transcriptional regulation of the DF3 gene expression in human MCF-7 breast carcinoma cells. J Cell Physiol 1990; 143: 226-231.
17. Abe M, Kufe D. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc Natl Acad Sci USA 1993; 90: 282-286.
18. Kovarik A, Peat N, Wilson D, Gendler S, Taylor-Papadimitriou J. Analysis of the tissue-specific promoter of the MUC1 gene. J Biol Chem 1993; 268: 9917-9926.
19. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C et al. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 2010; 29: 920-929.
20. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S, Kufe D. MUC1-C oncoprotein functions as a direct activator of the NF-kB p65 transcription factor. Cancer Res 2009; 69: 7013-7021.
21. Ahmad R, Rajabi H, Kosugi M, Joshi M, Alam M, Vasir B et al. MUC1-C oncoprotein promotes STAT3 activation in an auto-inductive regulatory loop. Sci Signal 2011; 4: ra9.
22. Rajabi H, Jin C, Ahmad R, McClary C, Kufe D. Mucin 1 oncoprotein expression is suppressed by the miR-125b oncomir. Genes & Cancer 2010; 1: 62-65.
23. Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70: 378-387.
24. Jin C, Rajabi H, Kufe D. miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. Int J Oncol 2010; 37: 61-69.
25. Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011; 121: 3797-3803.
26. Kufe D. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther 2009; 8: 1201-1207.
27. Khodarev N, Pitroda S, Beckett M, MacDermed D, Huang L, Kufe D et al. MUC1- induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 2009; 69: 2833-2837.
28. Pitroda S, Khodarev N, Beckett M, Kufe D, Weichselbaum R. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci USA 2009; 106: 5837-5841.
29. He C, Hobert M, Friend L, Carlin C. The epidermal growth factor receptor juxtamembrane domain has multiple basolateral plasma membrane localization determinants, including a dominant signal with a polyproline core. J Biol Chem 2002; 277: 38284-38293.
30. Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J et al. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 2003; 422: 322-326.
31. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 2007; 27: 992-1004.
32. Li Y, Ren J, Yu W, Li G, Kuwahara H, Yin L et al. The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and b-catenin. J Biol Chem 2001; 276: 35239-35242.
33. Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3b and b-catenin. J Biol Chem 2001; 276: 6061-6064.
34. Schroeder J, Thompson M, Gardner M, Gendler S. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001; 276: 13057-13064.
35. Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, Thompson MC et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004; 23: 5739-5747.
36. Pochampalli MR, Bitler BG, Schroeder JA. Transforming growth factor {alpha} dependent cancer progression is modulated by MUC1. Cancer Res 2007; 67: 6591-6598.
37. Merlin J, Stechly L, de Beauce S, Monte D, Leteurtre E, van Seuningen I et al. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 2011; 30: 2514-2525.
38. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 2011; 10: 806-816.
39. Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci 2010; 123: 1716-1723.
40. Li Y, Yu W-H, Ren J, Huang L, Kharbanda S, Loda M et al. Heregulin targets g-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 protein. Mol Cancer Res 2003; 1: 765-775.
41. Ren J, Raina D, Chen W, Li G, Huang L, Kufe D. MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res 2006; 4: 873-883.
42. Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K et al. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J Biol Chem 2008; 283: 26985-26995.
43. Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL et al. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 2007; 67: 5201-5210.
44. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-562.
45. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
46. Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-apoptotic PI3K/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 2004; 279: 20607-20612.
47. Horn G, Gaziel A, Wreschner DH, Smorodinsky NI, Ehrlich M. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res 2009; 315: 1490-1504.
48. Kato K, Lu W, Kai H, Kim KC. Phosphoinositide 3-kinase is activated by MUC1 but not responsible for MUC1-induced suppression of Toll-like receptor 5 signaling. Am J Physiol Lung Cell Mol Physiol 2007; 293: L686-L692.
49. Kosugi M, Ahmad R, Alam M, Uchida Y, Kufe D. MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS One 2011; 6: e28234.
50. Yao M, Zhang W, Zhang Q, Xing L, Xu A, Liu Q et al. Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways. Lung 2011; 189: 453-460.
51. Woo JK, Choi Y, Oh S-H, Jeong J-H, Choi D-H, Seo H-S et al. Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway. Oncogene 2012; 31: 2187-2198.
52. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995; 55: 4000-4003.
53. Meerzaman D, Shapiro PS, Kim KC. Involvement of the MAP kinase ERK2 in MUC1 mucin signaling. Am J Physiol Lung Cell Mol Physiol 2001; 281: L86-L91.
54. Kinlough CL, Poland PA, Bruns JB, Harkleroad KL, Hughey RP. MUC1 membrane trafficking is modulated by multiple interactions. J Biol Chem 2004; 279: 53071-53077.
55. Kinlough CL, McMahan RJ, Poland PA, Bruns JB, Harkleroad KL, Stremple RJ et al. Recycling of MUC1 is dependent on its palmitoylation. J Biol Chem 2006; 281: 12112-12122.
56. Liao HJ, Carpenter G. Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol Biol Cell 2007; 18: 1064-1072.
57. Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M et al. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem 2007; 282: 19321-19330.
58. Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S, Kufe D. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol 2012; 40: 1643-1649.
59. Ren J, Agata N, Chen D, Li Y, Yu W-H, Huang L et al. Human MUC1 carcinomaassociated protein confers resistance to genotoxic anti-cancer agents. Cancer Cell 2004; 5: 163-175.
60. Ren J, Bharti A, Raina D, Chen W, Ahmad R, Kufe D. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene 2006; 25: 20-31.
61. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45-51.
62. Yamamoto M, Bharti A, Li Y, Kufe D. Interaction of the DF3/MUC1 breast carcinoma- associated antigen and b-catenin in cell adhesion. J Biol Chem 1997; 272: 12492-12494.
63. Li Y, Bharti A, Chen D, Gong J, Kufe D. Interaction of glycogen synthase kinase 3b with the DF3/MUC1 carcinoma-associated antigen and b-catenin. Mol Cell Biol 1998; 18: 7216-7224.
64. Ren J, Li Y, Kufe D. Protein kinase C d regulates function of the DF3/MUC1 carcinoma antigen in b-catenin signaling. J Biol Chem 2002; 277: 17616-17622.
65. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003; 22: 1324-1332.
66. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003; 22: 6107-6110.
67. Wen Y, Caffrey T, Wheelock M, Johnson K, Hollingsworth M. Nuclear association of the cytoplasmic tail of MUC1 and b-catenin. J Biol Chem 2003; 278: 38029-38039.
68. Huang L, Ren J, Chen D, Li Y, Kharbanda S, Kufe D. MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther 2003; 2: 702-706.
69. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks GSK3b-mediated phosphorylation and degradation of b-catenin. Cancer Res 2005; 65: 10413-10422.
70. Li Y, Yi H, Yao Y, Liao X, Xie Y, Yang J et al. The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of beta-catenin. PLoS One 2011; 6: e19102.
71. Hoppler S, Kavanagh CL. Wnt signalling: variety at the core. J Cell Sci 2007; 120: 385-393.
72. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.